市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Celcuity Inc. | 混合的 | 看涨 |
AIStockmoo 评分
1.3
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 3.0 |
| 平均 | 1.33 |
|
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 13.21% |
| 机构持股比例 | 81.78% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Baker Bros. Advisors Lp | 31 Mar 2026 | 7,915,792 |
| Avoro Capital Advisors Llc | 31 Mar 2026 | 3,375,000 |
| Perceptive Advisors Llc | 31 Mar 2026 | 3,127,200 |
| Rtw Investments, Lp | 31 Mar 2026 | 3,039,621 |
| Nea Management Company, Llc | 31 Mar 2026 | 2,285,561 |
| Soleus Capital Management, L.P. | 31 Mar 2026 | 1,284,378 |
| Tang Capital Management Llc | 31 Mar 2026 | 1,050,000 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合